Clinical Trial Update: Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer

View source ↗

Summary

A clinical trial investigating biomarkers to predict immunotherapy efficacy in head and neck squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Snippet

Sponsor: Cofactor Genomics, Inc. | Conditions: Head and Neck Squamous Cell Carcinoma | Status: WITHDRAWN